{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:18Z","timestamp":1791228678784,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T00:00:00Z","timestamp":1443398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00277-015-2478-9","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T02:25:15Z","timestamp":1443407115000},"page":"2025-2032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings"],"prefix":"10.1007","volume":"94","author":[{"given":"Myron S.","family":"Czuczman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lamonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"issue":"Suppl 3","key":"2478_CR1","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O et al (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii83\u2013iii92","journal-title":"Ann Oncol"},{"issue":"11","key":"2478_CR2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"issue":"1","key":"2478_CR3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","volume":"80","author":"A Goy","year":"2011","unstructured":"Goy A, Kahl B (2011) Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 80(1):69\u201386","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2478_CR4","first-page":"683","volume":"23","author":"J Ruan","year":"2009","unstructured":"Ruan J, Coleman M, Leonard JP (2009) Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park) 23(8):683\u2013690","journal-title":"Oncology (Williston Park)"},{"issue":"15","key":"2478_CR5","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J Clin Oncol"},{"key":"2478_CR6","doi-asserted-by":"crossref","unstructured":"Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(27):4473\u20134479","DOI":"10.1200\/JCO.2008.17.0001"},{"issue":"7","key":"2478_CR7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00277-012-1422-5","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Cortelazzo S et al (2012) Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin\u2019s lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 91(7):1013\u20131022","journal-title":"Ann Hematol"},{"issue":"9873","key":"2478_CR8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"19","key":"2478_CR9","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt RH, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952","journal-title":"Blood"},{"issue":"7","key":"2478_CR10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3109\/10428194.2011.654342","volume":"53","author":"JE Chang","year":"2012","unstructured":"Chang JE, Kahl BS (2012) Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma 53(7):1249\u20131250","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2478_CR11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3747\/co.19.1064","volume":"19","author":"R Jagt van der","year":"2012","unstructured":"van der Jagt R, Laneuville P, MacDonald D, Stewart D, Christofides A, Sehn LH (2012) A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Curr Oncol 19(3):160\u2013168","journal-title":"Curr Oncol"},{"issue":"5","key":"2478_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"8","key":"2478_CR13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on Interim-PET-scan in lymphoma. Leuk Lymphoma 50(8):1257\u20131260","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2478_CR14","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL et al (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807\u20132812","journal-title":"Blood"},{"issue":"7","key":"2478_CR15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"R Weide","year":"2007","unstructured":"Weide R, Hess G, K\u00f6ppler H et al (2007) High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas: a multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 48(7):1299\u20131306","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2478_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V124.21.145.145","volume":"124","author":"MJ Rummel","year":"2014","unstructured":"Rummel MJ, Balser C, Kaiser U et al (2014) Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent, or mantle cell lymphomas\u20148-year follow-up results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood 124(21):145","journal-title":"Blood"},{"issue":"7","key":"2478_CR17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3109\/10428194.2011.649476","volume":"53","author":"S Warsch","year":"2012","unstructured":"Warsch S, Hosein PJ, Maeda LS, Alizadeh AA, Lossos IS (2012) A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 53(7):1299\u20131305","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2478_CR18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00277-014-2077-1","volume":"93","author":"A Garc\u00eda-Noblejas","year":"2014","unstructured":"Garc\u00eda-Noblejas A, Mart\u00ednez Chamorro C, Navarro Matilla B et al (2014) Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Ann Hematol 93(9):1551\u20131558","journal-title":"Ann Hematol"},{"issue":"18 Pt 1","key":"2478_CR19","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","volume":"13","author":"RC Kane","year":"2007","unstructured":"Kane RC, Dagher R, Farrell A et al (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13(18 Pt 1):5291\u20135294","journal-title":"Clin Cancer Res"},{"key":"2478_CR20","unstructured":"(2013) Revlimid [package insert]. Celgene Corporation; Summit, NJ"},{"issue":"14","key":"2478_CR21","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","volume":"118","author":"AR Mato","year":"2012","unstructured":"Mato AR, Svoboda J, Feldman T et al (2012) Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 118(14):3565\u20133570","journal-title":"Cancer"},{"issue":"10","key":"2478_CR22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","volume":"86","author":"PJ Hosein","year":"2011","unstructured":"Hosein PJ, Pastorini VH, Paes FM et al (2011) Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 86(10):841\u2013845","journal-title":"Am J Hematol"},{"issue":"11","key":"2478_CR23","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R et al (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442\u20131449","journal-title":"J Clin Oncol"},{"issue":"21","key":"2478_CR24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V124.21.148.148","volume":"124","author":"R Gressin","year":"2014","unstructured":"Gressin R, Callanan M, Daguindau N et al (2014) Frontline therapy with the Ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective phase II trial by the Lysa group. Blood 124(21):148","journal-title":"Blood"},{"issue":"1","key":"2478_CR25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S (2015) Mantle cell lymphoma: evolving management strategies. Blood 125(1):48\u201355","journal-title":"Blood"},{"issue":"1","key":"2478_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","volume":"9","author":"JA Burger","year":"2014","unstructured":"Burger JA (2014) Bruton\u2019s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 9(1):44\u201349","journal-title":"Curr Hematol Malig Rep"},{"key":"2478_CR27","unstructured":"A study of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantle cell lymphoma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01776840?term=ibrutinib+AND+phase+3+AND+mantle+cell+lymphoma&rank=2 . Accessed 21 May 2015"},{"issue":"6","key":"2478_CR28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516","journal-title":"N Engl J Med"},{"issue":"30","key":"2478_CR29","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874","journal-title":"J Clin Oncol"},{"issue":"29","key":"2478_CR30","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME et al (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 31(29):3688\u20133695","journal-title":"J Clin Oncol"},{"issue":"23","key":"2478_CR31","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822\u20133829","journal-title":"J Clin Oncol"},{"key":"2478_CR32","doi-asserted-by":"crossref","unstructured":"Wang M, Rule S, Martin P et al (2014) Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. Blood 124(21):445","DOI":"10.1182\/blood.V124.21.4453.4453"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2478-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2478-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2478-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T10:17:01Z","timestamp":1653214621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2478-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2478-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,28]]}}}